Concepedia

Publication | Open Access

Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors

DOIFull Paper Access

145

Citations

27

References

2018

Year

Stergios J. Moschos, Ryan J. Sullivan, Wen-Jen Hwu, Ramesh K. Ramanathan, Alex A. Adjei, Peter C.C. Fong, Ronnie Shapira‐Frommer, Hussein Tawbi, Joseph Rubino, Thomas S. Rush,
JCI Insight

Abstract

Merck Sharp & Dohme Corp., a subsidiary of Merck & Co. Inc., and NIH (P01 CA168585 and R35 CA197633).

References

YearCitations

Page 1